American Express
AXP
Bank of America
BAC
Occidental Petroleum
OXY
Citigroup
C
Chevron
CVX
US Stock MarketDetailed Quotes
RAPP Rapport Therapeutics
- 10.510
- +0.490+4.89%
Close Mar 14 16:00 ET
- 10.900
- +0.390+3.71%
Post 20:01 ET
383.58MMarket Cap-4.91P/E (TTM)
11.343High10.290Low185.77KVolume10.430Open10.020Pre Close2.00MTurnover1.25%Turnover RatioLossP/E (Static)36.50MShares29.74052wk High1.26P/B155.86MFloat Cap6.43052wk Low--Dividend TTM14.83MShs Float29.740Historical High--Div YieldTTM10.51%Amplitude6.430Historical Low10.765Avg Price1Lot Size
Rapport Therapeutics News
Pleasing Signs As A Number Of Insiders Buy Rapport Therapeutics Stock
Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares
Buy Rating Affirmed for Rapport Therapeutics Amid Promising RAP-219 Trials and Strong Financial Position
TD Cowen Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics | 10-K: FY2024 Annual Report
Rapport Therapeutics | 8-K: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the Year With $305.3M in Cash, Cash Equivalents, and Short-term Investments, Which Is Expected to Fund Operations Through the End of 2026
Rapport Therapeutics 4Q Loss/Shr 57c >RAPP
Press Release: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Express News | Rapport Therapeutics : Intends to Initiate Additional Phase 2a Trial of Rap-219 in Bipolar Mania in Q3 2025 With Topline Data Expected in H1 of 2027
Express News | Rapport Therapeutics Announces Appointment of DR. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
Press Release: Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Stifel Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $42
TD Cowen Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
Rapport Therapeutics, Inc. (RAPP) Receives a Buy From TD Cowen
Rapport Therapeutics' Promising Trial Results and Leadership Change
Stifel Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
Trending Stocks
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.